We found that patients characterized by CXCR4a had significantly reduced time to treatment (TTT) and patients characterized by the Eμ-TCL1;CXCR4C1013G vs Eμ-TCL1 signature had significantly reduced TTT and overall survival (Fig. 5f), further supporting the association of CXCR4 hyperactivation with aggressive lymphoma biology. This evidence concerns the gene CXCR4 and lymphoma.